Aliases & Classifications for Vitreous Detachment

MalaCards integrated aliases for Vitreous Detachment:

Name: Vitreous Detachment 12 45 15 17 74
Posterior Vitreous Detachment 74

Classifications:



External Ids:

Disease Ontology 12 DOID:9726
MeSH 45 D020255
NCIt 51 C50807
SNOMED-CT 69 53772007
ICD10 34 H43.81

Summaries for Vitreous Detachment

MalaCards based summary : Vitreous Detachment, also known as posterior vitreous detachment, is related to macular retinal edema and endophthalmitis, and has symptoms including eye manifestations An important gene associated with Vitreous Detachment is KCNMA1 (Potassium Calcium-Activated Channel Subfamily M Alpha 1), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Degradation of the extracellular matrix. The drugs Bevacizumab and Temazepam have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and endothelial, and related phenotypes are cardiovascular system and growth/size/body region

Wikipedia : 77 A posterior vitreous detachment (PVD) is a condition of the eye in which the vitreous membrane separates... more...

Related Diseases for Vitreous Detachment

Diseases related to Vitreous Detachment via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 43)
# Related Disease Score Top Affiliating Genes
1 macular retinal edema 30.4 KCNMA1 VEGFA
2 endophthalmitis 29.9 PLG VEGFA
3 macular holes 29.6 KCNMA1 LHFPL5 VEGFA
4 macular degeneration, age-related, 1 29.6 KCNMA1 OPTC PLG VEGFA
5 retinal detachment 10.5
6 microvascular complications of diabetes 5 10.3
7 diabetic macular edema 10.3
8 cataract 10.2
9 retinal vein occlusion 10.2
10 myopia 10.2
11 diabetes mellitus 10.0
12 kuhnt-junius degeneration 10.0
13 optic nerve disease 10.0
14 neuropathy 10.0
15 optic disc pit 10.0
16 optic disk drusen 9.9 KCNMA1 VEGFA
17 chronic myocardial ischemia 9.9 PLG VEGFA
18 blood group, globoside system 9.9 PLG VEGFA
19 exudative vitreoretinopathy 1 9.9
20 systemic lupus erythematosus 9.9
21 vitreoretinopathy, neovascular inflammatory 9.9
22 nonarteritic anterior ischemic optic neuropathy 9.9
23 retinitis pigmentosa 9.9
24 microvascular complications of diabetes 1 9.9
25 leber congenital amaurosis 4 9.9
26 pars planitis 9.9
27 microvascular complications of diabetes 2 9.9
28 ischemic optic neuropathy 9.9
29 isolated ectopia lentis 9.9
30 central retinal artery occlusion 9.9
31 central retinal vein occlusion 9.9
32 retinitis 9.9
33 retinal disease 9.9
34 retinal artery occlusion 9.9
35 lupus erythematosus 9.9
36 retinal vascular occlusion 9.9 PLG VEGFA
37 hepatic veno-occlusive disease 9.8 PLG VEGFA
38 vein disease 9.8 PLG VEGFA
39 corneal neovascularization 9.8 PLG VEGFA
40 retinal vascular disease 9.7 PLG VEGFA
41 vitreous disease 9.7 OPTC PLG VEGFA
42 arteries, anomalies of 9.7 PLG VEGFA
43 differentiated thyroid carcinoma 9.5 FN1 VEGFA

Graphical network of the top 20 diseases related to Vitreous Detachment:



Diseases related to Vitreous Detachment

Symptoms & Phenotypes for Vitreous Detachment

UMLS symptoms related to Vitreous Detachment:


eye manifestations

MGI Mouse Phenotypes related to Vitreous Detachment:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.73 FN1 KCNMA1 LAMA5 OPTC PLG VEGFA
2 growth/size/body region MP:0005378 9.63 FN1 KCNMA1 LAMA5 PLG SLC44A2 VEGFA
3 hearing/vestibular/ear MP:0005377 9.26 KCNMA1 LAMA5 LHFPL5 SLC44A2
4 nervous system MP:0003631 9.17 FN1 KCNMA1 LAMA5 LHFPL5 PLG SLC44A2

Drugs & Therapeutics for Vitreous Detachment

Drugs for Vitreous Detachment (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 47)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4,Not Applicable 216974-75-3
2
Temazepam Approved, Investigational Phase 4 846-50-4 5391
3
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
4
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
5 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 1,Not Applicable
6 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 1,Not Applicable
7 Antineoplastic Agents, Immunological Phase 4,Not Applicable
8 Central Nervous System Depressants Phase 4
9 Peripheral Nervous System Agents Phase 4
10 Anti-Inflammatory Agents Phase 4,Phase 3
11 HIV Protease Inhibitors Phase 4
12 Hormones Phase 4,Phase 3
13
protease inhibitors Phase 4
14 Autonomic Agents Phase 4
15 BB 1101 Phase 4
16 Psychotropic Drugs Phase 4
17 Neurotransmitter Agents Phase 4
18 Anti-Anxiety Agents Phase 4
19 Antineoplastic Agents, Hormonal Phase 4
20 Hormone Antagonists Phase 4,Phase 3
21 Antiemetics Phase 4
22 GABA Modulators Phase 4
23 GABA Agents Phase 4
24 Gastrointestinal Agents Phase 4
25 glucocorticoids Phase 4,Phase 3
26 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3
27 Hypnotics and Sedatives Phase 4
28 Tranquilizing Agents Phase 4
29 Pharmaceutical Solutions Phase 4,Phase 2
30
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
31 Plasminogen Phase 3,Phase 2,Phase 1,Not Applicable
32 Fibrinolytic Agents Phase 3,Phase 2,Phase 1,Not Applicable
33 Immunosuppressive Agents Phase 3
34 Triamcinolone hexacetonide Phase 3
35 triamcinolone acetonide Phase 3
36 Immunologic Factors Phase 3
37 Triamcinolone diacetate Phase 3
38
Ranibizumab Approved Phase 2,Phase 1,Not Applicable 347396-82-1 459903
39
Fibrinolysin Investigational Phase 2,Phase 1 9004-09-5
40 Ophthalmic Solutions Phase 2
41 Mitogens Phase 2
42 Endothelial Growth Factors Phase 2
43
Dipivefrin Approved Not Applicable 52365-63-6 3105
44 Diminazene aceturate Not Applicable
45 Proxymetacaine
46 Tetrahydrozoline Not Applicable
47 Tissue Plasminogen Activator Not Applicable

Interventional clinical trials:

(show all 47)
# Name Status NCT ID Phase Drugs
1 Combined Therapy in Age-Related Macular Degeneration (ARMD) Completed NCT00805649 Phase 4 dexamethasone;bevacizumab;triamcincolone
2 Assessment of Patients Treated With JETREA® for Vitreomacular Traction Completed NCT02035748 Phase 4 Ocriplasmin
3 Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion Completed NCT02322229 Phase 4 Ocriplasmin 0.125 mg in a 0.1 mL volume
4 A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects Unknown status NCT00908778 Phase 3 Vitreosolve;Vitreosolve
5 Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-006) Trial. Completed NCT00781859 Phase 3 125 µg Ocriplasmin;Placebo
6 Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-007) Trial. Completed NCT00798317 Phase 3 Ocriplasmin 125µg;Placebo
7 Laser Versus Vitrectomy Versus Intravitreal Triamcinolone Injection for Diabetic Macular Edema Completed NCT00764244 Phase 3 Intravitreal triamcinolone injections
8 Combined Vitrectomy and Triamcinolone in Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO) Terminated NCT00642226 Phase 3
9 Assessment of Intravitreous Injections of Vitrase for Inducing Posterior Vitreous Detachment Completed NCT00198471 Phase 2 Vitrase
10 Posterior Vitreous Detachment (PVD) Assessment During Dual Retinal Vein Occlusion (RVO) Lucentis Evaluations Completed NCT00831350 Phase 2 Ranibizumab
11 A Study of the Safety and Efficacy of Microplasmin to Induce a Posterior Vitreous Detachment (MIVI III) Completed NCT00412958 Phase 2 Ocriplasmin 25µg;Ocriplasmin 75µg;Ocriplasmin 125µg;Placebo
12 A Study to Compare Multiple Doses Intravitreal Microplasmin for Treatment of Patients With Vitreomacular Traction (MIVI-IIt) Completed NCT00435539 Phase 2 ocriplasmin;ocriplasmin;Sham Comparator
13 A Multicenter Study to Compare Multiple Doses of Intravitreal Microplasmin Versus Sham Injection for Treatment of Patients With Diabetic Macular Edema (DME) Completed NCT00412451 Phase 2 ocriplasmin
14 A Clinical Trial Designed to Evaluate the Safety and Efficacy Study of Luminate® in Inducing PVD (Posterior Vitreous Detachment) in Non-Proliferative Diabetic Retinopathy Completed NCT02435862 Phase 2 1.0mg Luminate®;2.0mg Luminate®;3.0mg Luminate®
15 Clinical Trial of Intravitreal Microplasmin in Infants and Children Scheduled for Vitrectomy Completed NCT00986362 Phase 2 Ocriplasmin;Placebo
16 Intravitreal Microplasmin in Patients Undergoing Surgical Vitrectomy Completed NCT00123279 Phase 2 Microplasmin
17 Safety and Efficacy Study of Microplasmin in for Non-Surgical Treatment of Focal Vitreomacular Adhesion Completed NCT01055535 Phase 2 Microplasmin
18 An Extension to Study MD7108240 Completed NCT00733304 Phase 2 Pazopanib
19 A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR Active, not recruiting NCT02681809 Phase 2 ocriplasmin 0.0625mg;ocriplasmin 0.125mg;Sham injection
20 A Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment (PVD) Terminated NCT00347646 Phase 1, Phase 2 Plasmin
21 Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment Terminated NCT00348439 Phase 2 Plasmin;Vehicle
22 Microplasmin Intravitreal Administration in Participants With Uveitic Macular Edema Terminated NCT01194674 Phase 1, Phase 2 Microplasmin
23 Partial Posterior Hyaloidectomy in Macular Surgery Completed NCT01454466 Phase 1
24 Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial Completed NCT00363168 Phase 1 Ranibizumab;Ranibizumab
25 A Study to Evaluate the Safety and Tolerability of ONL1204 in Patients With Macula-off, Rhegmatogenous Retinal Detachment Not yet recruiting NCT03780972 Phase 1 ONL1204
26 Vitreopapillary Interface and Optic Disc Morphology Unknown status NCT02290795
27 Intravitreal Injection of Bevacizumab and Gas for Diabetic Premacular Hemorrhage With Active Fibrovascular Proliferation Unknown status NCT00673296 Not Applicable Intravitreal Bevacizumab
28 Comparison of Two Techniques for Epiretinal or Internal Limiting Membrane Peel Unknown status NCT00892619 Not Applicable
29 Triple Therapy for Diffuse Diabetic Macular Edema Unknown status NCT01218750 Not Applicable
30 Annular Array Ultrasound in Ophthalmology Completed NCT01415037
31 YAG Vitreolysis for Floaters Completed NCT02897583 Not Applicable
32 High-frequency-ultrasound Annular Arrays for Ophthalmic Imaging Completed NCT00633854
33 Intravitreal Ranibizumab in Exudative Age-related Macular Degeneration With Posterior Vitreomacular Adhesion Completed NCT01291121 Not Applicable
34 Clear Vision Study Completed NCT01970267 Not Applicable
35 Evaluation of the Effect of Vitreous Composition Determined by Ultrasound and Optical Coherence Tomography (OCT) on Ranibizumab Therapy Completed NCT01256632 Not Applicable Ranibizumab
36 Ultrastructure Analysis of Excised Internal Limiting Membrane in Eyes of Highly Myopia With Myopic Traction Maculopathy Completed NCT02528058
37 Comparison of a Spectral OCT/SLO With the Stratus OCT for Imaging Various Retinal Pathologies Completed NCT00408720
38 Prevalence of Vitreomacular Adhesion in Patients 40 Years and Older Completed NCT02160340
39 A Long-Term Safety Study of OZURDEX® in Clinical Practice Completed NCT01539577 dexamethasone 700 μg intravitreal implant
40 Outcomes of Vitrectomy in Pediatric Retinal Detachment With Proliferative Vitreoretinopathy Completed NCT03208205
41 Vitrectomy for Branch Retinal Vein Occlusion Completed NCT00685490
42 Retinal Layers and Visual Rehabilitation After Epiretinal Membrane Removal Completed NCT01474655 Not Applicable
43 Vitrectomy for Optic Disc Pit Maculopathy Completed NCT01340703 Not Applicable
44 Influence of Posterior Vitreous Detachment on Retinal Detachment After Lens Surgery in Myopic Eyes Recruiting NCT03152747
45 Chart Review: Drug Utilization Study in Participants Who Received Ozurdex™ (Dexamethasone Intravitreal Implant) 0.7 mg Injections for Visual Impairment Due to Diabetic Macular Edema (DME) Active, not recruiting NCT03889444
46 Effect on the Vitreous of the Not Complicated Surgery of the Cataract to the Emmetropic Patient Terminated NCT02783209 Not Applicable
47 Evaluation of the Role of Intravitreal Tissue Plasminogen Activator in Treatment of Refractory Diabetic Macular Edema Terminated NCT01141881 Not Applicable Tissue Plasminogen Activator,bevacizumab ,follow up

Search NIH Clinical Center for Vitreous Detachment

Cochrane evidence based reviews: vitreous detachment

Genetic Tests for Vitreous Detachment

Anatomical Context for Vitreous Detachment

MalaCards organs/tissues related to Vitreous Detachment:

42
Eye, Retina, Endothelial, Cortex

Publications for Vitreous Detachment

Articles related to Vitreous Detachment:

(show top 50) (show all 273)
# Title Authors Year
1
Absence of Posterior Vitreous Detachment Is a Risk Factor of Severe Bleb-Related Endophthalmitis. ( 30755799 )
2019
2
Symptoms related to posterior vitreous detachment and the risk of developing retinal tears: a systematic review. ( 30632695 )
2019
3
Indocyanine Green-Assisted Internal Limiting Membrane Peeling to Induce Posterior Vitreous Detachment in the Cases With Strong Vitreoretinal Adhesion. ( 30893274 )
2019
4
Retinal detachment after acute posterior vitreous detachment resulting from posterior chamber phakic intraocular lens implantation. ( 29502596 )
2018
5
Can emergency physicians accurately distinguish retinal detachment from posterior vitreous detachment?: A response. ( 29793773 )
2018
6
Central retinal artery occlusion during vitrectomy: Immediate retinal revascularization following induction of posterior vitreous detachment. ( 29468216 )
2018
7
Posterior Vitreous Detachment as Observed by Wide-Angle OCT Imaging. ( 29631900 )
2018
8
Can emergency physicians accurately distinguish retinal detachment from posterior vitreous detachment with point-of-care ocular ultrasound? ( 29784278 )
2018
9
Posterior Vitreous Detachment Precipitated by Yoga. ( 29581921 )
2018
10
Bilateral Posterior Vitreous Detachment in a Young Patient with Systemic Lupus Erythematosus. ( 30057865 )
2018
11
FULL DIAGNOSTIC VITRECTOMY WITH POSTERIOR VITREOUS DETACHMENT INDUCTION FOR THE DIAGNOSIS OF VITRITIS DUE TO UNCERTAIN ETIOLOGY. ( 30005004 )
2018
12
Comment on "Ultrasound reliability in detection of retinal tear in acute symptomatic posterior vitreous detachment with vitreous hemorrhage". ( 30046548 )
2018
13
Posterior Vitreous Detachment. ( 30143091 )
2018
14
Post-Traumatic Giant Retinal Tear Without Posterior Vitreous Detachment: A Case Series. ( 30222803 )
2018
15
The vitreopapillary interface in healthy and glaucoma: posterior vitreous detachment in the vitreopapillary interface study. ( 30280516 )
2018
16
The role of posterior vitreous detachment on the efficacy of anti-vascular endothelial growth factor intravitreal injection for treatment of neovascular age-related macular degeneration. ( 30451182 )
2018
17
Early posterior vitreous detachment is associated with LAMA5 dominant mutation. ( 30589377 )
2018
18
Ultrasound reliability in detection of retinal tear in acute symptomatic posterior vitreous detachment with vitreous hemorrhage. ( 29259914 )
2017
19
Myopia as a risk factor for subsequent retinal tears in the course of a symptomatic posterior vitreous detachment. ( 29191240 )
2017
20
Can emergency physicians accurately distinguish retinal detachment from posterior vitreous detachment with point-of-care ocular ultrasound? ( 29042095 )
2017
21
Cost-Utility of Evaluation for Posterior Vitreous Detachment and Prophylaxis of Retinal Detachment. ( 28732590 )
2017
22
Assessment of posterior vitreous detachment on enhanced high density line optical coherence tomography. ( 28149795 )
2017
23
Degradation of Contrast Sensitivity Function Following Posterior Vitreous Detachment. ( 28236439 )
2017
24
Response to Re: Evaluation of posterior vitreous detachment after uneventful phacoemulsification surgery by optical coherence tomography and ultrasonography. ( 28971519 )
2017
25
The Role of Posterior Vitreous Detachment and Vitreomacular Adhesion in Patients With Age-Related Macular Degeneration. ( 28297034 )
2017
26
Re: Evaluation of posterior vitreous detachment after uneventful phacoemulsification surgery by optical coherence tomography and ultrasonography. ( 28975671 )
2017
27
Posterior vitreous detachment - prevalence of and risk factors for retinal tears. ( 29075095 )
2017
28
Risk factors for multiple retinal tears in patients with acute posterior vitreous detachment. ( 28160191 )
2017
29
An unusual pathological posterior vitreous detachment. ( 28503754 )
2017
30
PARS PLANA VITRECTOMY AND LENSECTOMY FOR ECTOPIA LENTIS WITH AND WITHOUT THE INDUCTION OF A POSTERIOR VITREOUS DETACHMENT. ( 28207607 )
2017
31
Posterior Vitreous Detachment and the Posterior Hyaloid Membrane. ( 28867131 )
2017
32
PERIPAPILLARY RETINAL NERVE FIBER THICKNESS CHANGES AFTER VITRECTOMY FOR EPIRETINAL MEMBRANE IN EYES WITH AND WITHOUT VITREOUS DETACHMENT. ( 28098728 )
2017
33
NOVEL SURGICAL TECHNIQUE FOR INDUCING POSTERIOR VITREOUS DETACHMENT DURING PARS PLANA VITRECTOMY FOR PEDIATRIC PATIENTS USING A FLEXIBLE LOOP. ( 29176537 )
2017
34
Optic Nerve Head Hemorrhages Associated With Posterior Vitreous Detachment. ( 29063741 )
2017
35
Vitreous Hyper-Reflective Dots in Optical Coherence Tomography and Retinal Tear in Patients with Acute Posterior Vitreous Detachment. ( 28358220 )
2017
36
Incidence of Posterior Vitreous Detachment After Femtosecond LASIK Compared With Microkeratome LASIK. ( 28708815 )
2017
37
Posterior vitreous detachment and macular anatomical changes - a tomographic-electroretinographic study. ( 27833968 )
2016
38
Possible Relation between Lack of Posterior Vitreous Detachment and Severe Endogenous Endophthalmitis. ( 27766175 )
2016
39
Ranibizumab Versus Bevacizumab for Neovascular Age-Related Macular Degeneration With an Incomplete Posterior Vitreous Detachment. ( 26692256 )
2016
40
Prevalence of posterior vitreous detachment in glaucoma patients and controls. ( 27966831 )
2016
41
Posterior Vitreous Detachment Associated with Non-arteritic Ischaemic Optic Neuropathy. ( 27928412 )
2016
42
SCLERAL BUCKLE SURGERY FOR PRIMARY RETINAL DETACHMENT WITHOUT POSTERIOR VITREOUS DETACHMENT. ( 27172097 )
2016
43
Spectral domain optical coherence tomography and B-scan ultrasonography in the evaluation of retinal tears in acute, incomplete posterior vitreous detachment. ( 27215604 )
2016
44
Evaluation of posterior vitreous detachment after uneventful phacoemulsification surgery by optical coherence tomography and ultrasonography. ( 27435335 )
2016
45
Partial posterior vitreous detachment as a classification criterion of epiretinal membrane. ( 26929594 )
2016
46
Degradation of Contrast Sensitivity Function Following Posterior Vitreous Detachment. ( 27633841 )
2016
47
Induction of Posterior Vitreous Detachment in Pediatric Vitrectomy by Preoperative Intravitreal Injection of Tissue Plasminogen Activator. ( 27018884 )
2016
48
Relationship between variations in posterior vitreous detachment and visual prognosis in idiopathic epiretinal membranes. ( 26730176 )
2016
49
Surgical induction of posterior vitreous detachment using combined sharp dissection and active aspiration. ( 26833701 )
2016
50
POSTERIOR VITREOUS DETACHMENT IN HIGHLY MYOPIC EYES UNDERGOING VITRECTOMY. ( 26669837 )
2016

Variations for Vitreous Detachment

Expression for Vitreous Detachment

Search GEO for disease gene expression data for Vitreous Detachment.

Pathways for Vitreous Detachment

GO Terms for Vitreous Detachment

Cellular components related to Vitreous Detachment according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 FN1 LAMA5 OPTC PLG VEGFA
2 collagen-containing extracellular matrix GO:0062023 9.33 FN1 LAMA5 PLG
3 basement membrane GO:0005604 9.32 FN1 LAMA5
4 extracellular matrix GO:0031012 9.26 FN1 LAMA5 OPTC VEGFA
5 platelet alpha granule lumen GO:0031093 8.8 FN1 PLG VEGFA

Biological processes related to Vitreous Detachment according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.54 FN1 LAMA5 VEGFA
2 angiogenesis GO:0001525 9.43 FN1 LAMA5 VEGFA
3 substrate adhesion-dependent cell spreading GO:0034446 9.32 FN1 LAMA5
4 branching morphogenesis of an epithelial tube GO:0048754 9.16 LAMA5 VEGFA
5 platelet degranulation GO:0002576 9.13 FN1 PLG VEGFA
6 interaction with symbiont GO:0051702 8.62 FN1 PLG

Molecular functions related to Vitreous Detachment according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.13 FN1 LAMA5 PLG
2 extracellular matrix structural constituent GO:0005201 8.8 FN1 LAMA5 OPTC

Sources for Vitreous Detachment

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....